Inflammation in Peritoneal Dialysis Patients: Effect of Obesity

This study is currently recruiting participants.
Verified September 2012 by University of Illinois at Chicago
Sponsor:
Information provided by (Responsible Party):
Jerrold S. Levine, University of Illinois at Chicago
ClinicalTrials.gov Identifier:
NCT01691196
First received: September 17, 2012
Last updated: December 17, 2013
Last verified: September 2012
  Purpose

Our study addresses the following research question: What is the role of obesity in modulating inflammation and innate immune function, as well as the overall responsiveness of innate immune cells (such as macrophages, neutrophils, and other peripheral leukocytes) in patients undergoing peritoneal dialysis?

The investigators hypothesize that obesity will lead to increased inflammation in patients undergoing peritoneal dialysis.


Condition
End-Stage Renal Disease
Renal Disease, End-Stage
Renal Failure, End-Stage
Obesity

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Inflammation in Peritoneal Dialysis Patients: Effect of Obesity

Resource links provided by NLM:


Further study details as provided by University of Illinois at Chicago:

Primary Outcome Measures:
  • Plasma and dialysate levels of pro-inflammatory and anti-inflammatory molecules [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
    Peritoneal dialysate effluent (PDE) and peripheral blood will be obtained from peritoneal dialysis (PD) subjects. Levels of pro- and anti-inflammatory cytokines, chemokines, adipokines, and acute-phase reactants will be evaluated in PDE and plasma. The ability of peripheral leukocytes to respond to microbial stimuli will be studied using whole blood cultures. We predict percentage of body fat will be significantly associated with higher levels of pro-inflammatory factors both systemically and locally and with reduced ability of peripheral leukocytes to respond to microbial stimuli.


Secondary Outcome Measures:
  • Peritoneal macrophage subphenotype [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
    The composition of leukocytes from peritoneal dialysate effluent (PDE) will be analyzed to evaluate the absolute and relative amounts of leukocyte subclasses. The phenotype of peritoneal macrophages (pMac) will be evaluated by flow cytometry, by real time RT-PCR, and by measurement of mediators characteristic of each activation type following ex vivo culture. We predict that we will observe a significant shift from an anti- to a pro-inflammatory pMac phenotype as adiposity increases


Other Outcome Measures:
  • Measurement of adiposity/obesity [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
    DXA (dual energy X-ray absorptiometry) will be conducted at UIC body composition laboratory using Hologic 4500 W Elite Scan. Values from DXA scans will be primary method for evaluation of adiposity. Height and weight will be measured by nurse to calculate body mass index (BMI).


Biospecimen Retention:   Samples Without DNA

Blood Collection: Venous blood after overnight fast will include: (1) heparinized tube (green top) for whole blood (WB) cultures; (2) EDTA tube (lavender top) for CBC and measurement of cytokines and adipokines, and (3) serum-separator (red top) for determination of lipid panel, glucose, insulin, and hemoglobin A1c. Glucose and insulin will be used to calculate HOMA-IR (index of insulin resistance).

Collection of peritoneal dialysis effluent (PDE): To minimize variability, 2.5% glucose peritoneal dialysis (PD) solution and 4h dwell time will be used for all patients on test day. Immediately after collection, PDE will be chilled before further processing.


Estimated Enrollment: 50
Study Start Date: September 2012
Estimated Study Completion Date: September 2014
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Detailed Description:

Chronic inflammation is highly prevalent in ESRD and associated with adverse outcomes. For example, chronic exposure of the peritoneal cavity to PD solution leads to induction of cytokines and other inflammatory mediators, generating peritoneal membrane inflammation which results in functional decline of ultrafiltration. Obesity is characterized by a state of chronic low-grade systemic inflammation stemming from expanded adipose tissue mass. Animal studies from our group and others suggest that obesity is associated with exacerbated prolonged inflammatory responses in the peritoneal cavity. The shifting demographic characteristics of the ESRD population, with a rise in elderly patients and those with obesity, is as a significant challenge for management of dialysis patients. Specifically, a 2-fold increase in the percentage of obese patients in the ESRD population has been reported. The caloric burden of PD glucose-containing solutions adds an additional risk for development or exacerbation of obesity and diabetes in patients using this dialysis modality. Few studies have directly evaluated the association between degree of adiposity and inflammation in PD patients. Data obtained from the proposed experiments will help clarify the connection between obesity and risk factors for cardiovascular and infectious diseases in the PD population. These data will also further our knowledge of the basic pathophysiology of both obesity and ESRD and enhance our understanding of factors involved in successful delivery of PD. Results may lead to enhanced nutritional recommendations for PD patients and/or the use of low-glucose or non-glucose alternatives, with a resultant reduction in local and/or systemic inflammation and CVD and other risk factors.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients undergoing peritoneal dialysis

Criteria

Inclusion Criteria:

  1. > 18 years; and
  2. peritoneal dialysis (PD) > 6 months.

Exclusion Criteria:

  1. infectious episode within 4 weeks; and
  2. using immunosuppressive drugs
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01691196

Contacts
Contact: Natalia Litbarg, MD 312-996-7378 nlitbarg@uic.edu
Contact: Giamila Fantuzzi, PhD 312-413-5398 giamila@uic.edu

Locations
United States, Illinois
University of Illinois at Chicago Recruiting
Chicago, Illinois, United States, 60612
Contact: Natalia Litbarg, MD    312-996-6736    nlitbarg@uic.edu   
Contact: Giamila Fantuzzi, PhD    312-413-5398    giamila@uic.edu   
Principal Investigator: Jerrold S Levine, MD         
Principal Investigator: Natalia Litbarg, MD         
Principal Investigator: Giamila Fantuzzi, PhD         
Sponsors and Collaborators
University of Illinois at Chicago
Investigators
Principal Investigator: Jerrold S Levine, MD UIC
Principal Investigator: Natalia Litbarg, MD UIC
Principal Investigator: Giamila Fantuzzi, PhD UIC
  More Information

No publications provided

Responsible Party: Jerrold S. Levine, Associate Professor of Medicine, University of Illinois at Chicago
ClinicalTrials.gov Identifier: NCT01691196     History of Changes
Other Study ID Numbers: Baxter/UIC Ref#2012-04881
Study First Received: September 17, 2012
Last Updated: December 17, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by University of Illinois at Chicago:
Obesity
Peritoneal dialysis
Inflammation
Macrophages
Innate immunity

Additional relevant MeSH terms:
Inflammation
Kidney Diseases
Kidney Failure, Chronic
Obesity
Renal Insufficiency
Pathologic Processes
Urologic Diseases
Renal Insufficiency, Chronic
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms

ClinicalTrials.gov processed this record on April 17, 2014